Ryan Patrick Radecki, MD, MS, is an emergency physician and informatician with Christchurch Hospital in Christchurch,
New Zealand. He is the Annals of Emergency
Medicine podcast co-host and Journal Club editor and can be found on Twitter @emlitofnote.
View this author's posts »
3 Responses to “Factors Driving Expanded Use of Tissue Plasminogen Activator for Acute Ischemic Stroke”
May 1, 2016
John HipskindThanks. You are one of the many sources I follow. Jerry Hoffman is another so you can guess most of the rest of this email.
TPA kills and this is simply an attempt to expand Genentech’s war zone. Bad enough we have this debate in the house of EM without these jerks weighing in.
I’ll accept ACC guidelines when they let ACEP determine cardiology treatment guidelines (and pay me to do so under the guise of expert opinion).
Keep up the great work.
May 18, 2016
jeffrey thewesYes, and why does no one point out the fact that the bleed rate in the 3-4.5 hour window was high. I didn’t see the exclusion criteria, but it sounds like the placebo group did not exclude strokes caused from bleeds. If the placebo group was sicker it makes the treatment group look better.
January 1, 2017
jim clearyIn my experience as one physician and the use of TPA, it has not proven to be the great “healer” it was espoused to be. Jim R Cleary MD FACEP